US Stocks Unusual Movement: VeraDermics surged on October 21 as Phase III trial met endpoints and oral hair loss medication was announced

VeraDermics October 21 Significant Surge Interpretation

Keywords: Phase III trial meets endpoints, oral hair loss medication

1. On October 19, 2026, the company announced the topline results of the VDPHL01 Phase III Study 304 for male pattern hair loss. A total of 536 participants took part in the trial, and the study met all primary and secondary endpoints. After 6 months of treatment, the target area non-vellus hair count increased by 28.6 hairs/cm² for the once-daily group and 36.4 hairs/cm² for the twice-daily group, compared to an increase of 6.6 hairs/cm² in the placebo group.

2. On October 19, 2026, the company disclosed that as early as the second month, the treatment groups showed statistically significant differences from the placebo group in hair count, patient-reported outcomes, and investigator assessments. No treatment-related serious adverse events or cardiovascular events of special interest were observed during the study period.

(Disclaimer: This content is generated by AI technology based on publicly available information for reference only and does not constitute investment advice.)